Cite
Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers.
MLA
Hong, David S., et al. “Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers.” Clinical Advances in Hematology & Oncology, vol. 22, July 2024, pp. 1–5. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178706219&authtype=sso&custid=ns315887.
APA
Hong, D. S., Drilon, A., & Wirth, L. J. (2024). Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers. Clinical Advances in Hematology & Oncology, 22, 1–5.
Chicago
Hong, David S., Alexander Drilon, and Lori J. Wirth. 2024. “Efficacy and Safety of NTRK Inhibitors in Patients With NTRK Fusion-Positive Lung and Thyroid Cancers.” Clinical Advances in Hematology & Oncology 22 (July): 1–5. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178706219&authtype=sso&custid=ns315887.